- Home
- LVO vs TCRX Comparison
LVO vs TCRX Comparison
Compare LVO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- TCRX
- Stock Information
- Founded
- LVO 2009
- TCRX 2018
- Country
- LVO United States
- TCRX United States
- Employees
- LVO N/A
- TCRX N/A
- Industry
- LVO Restaurants
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LVO Consumer Discretionary
- TCRX Health Care
- Exchange
- LVO Nasdaq
- TCRX Nasdaq
- Market Cap
- LVO 117.0M
- TCRX 115.8M
- IPO Year
- LVO N/A
- TCRX 2021
- Fundamental
- Price
- LVO $0.84
- TCRX $2.17
- Analyst Decision
- LVO Strong Buy
- TCRX Strong Buy
- Analyst Count
- LVO 2
- TCRX 5
- Target Price
- LVO $2.75
- TCRX $11.40
- AVG Volume (30 Days)
- LVO 858.3K
- TCRX 382.5K
- Earning Date
- LVO 02-13-2025
- TCRX 03-05-2025
- Dividend Yield
- LVO N/A
- TCRX N/A
- EPS Growth
- LVO N/A
- TCRX N/A
- EPS
- LVO N/A
- TCRX N/A
- Revenue
- LVO $126,016,000.00
- TCRX $9,362,000.00
- Revenue This Year
- LVO $5.30
- TCRX N/A
- Revenue Next Year
- LVO N/A
- TCRX $5.14
- P/E Ratio
- LVO N/A
- TCRX N/A
- Revenue Growth
- LVO 11.43
- TCRX N/A
- 52 Week Low
- LVO $0.56
- TCRX $1.99
- 52 Week High
- LVO $2.15
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- LVO 34.54
- TCRX 37.12
- Support Level
- LVO $0.82
- TCRX $2.02
- Resistance Level
- LVO $0.95
- TCRX $2.17
- Average True Range (ATR)
- LVO 0.13
- TCRX 0.16
- MACD
- LVO -0.04
- TCRX 0.02
- Stochastic Oscillator
- LVO 3.13
- TCRX 26.47
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.